started · updated
Anvisa regulates weight-loss medications and seizes irregular supplements
The Brazilian National Health Surveillance Agency (Anvisa) has taken significant regulatory actions regarding weight-loss medications and various health products. The agency approved two new injectable semaglutide-based medications, including a generic version and the similar drug Loryvia, for the treatment of type 2 diabetes. These approvals bring the total number of registered GLP-1 receptor agonist pens to 22 in 2026, following the expiration of the patent for Novo Nordisk’s Ozempic.
Simultaneously, Anvisa ordered the seizure and prohibition of several irregular products. This includes the weight-loss product Ultra Shape and various plant-based capsules from Ciência da Natureza, which lacked proper sanitary registration. The agency also targeted several dietary supplements sold on platforms like Shopee and Mercado Livre, including brands such as W Nutry, Muuh Magic, Vittacaps, and a specific lot of Essencial Nutrition’s Kit 3 Ômega Core, which the manufacturer did not recognize.
Additionally, Anvisa issued notices regarding quality deviations for Halexminophen and the seizure of Trodelvy lots intended for the Turkish market. In a separate policy development, the Brazilian Ministry of Health is exploring the inclusion of GLP-1 medications in the Unified Health System (SUS) by 2027 to treat obesity and reduce long-term healthcare costs.
Entities
Anvisa · Brazil · Ciência da Natureza Eireli · Gilead · Gilead Sciences · Halex · Ministry of Health · Novo Nordisk · Ávita Care Importação e Distribuição de Produtos Ltda.